science wire

« BACK

Pharmacology



Results 1051 - 1100 of 1530.


Health - Pharmacology - 15.11.2014
Novartis presents ground-breaking Phase III results showing AIN457 (secukinumab) significant efficacy in ankylosing spondylitis patients
More than 60% of secukinumab 150 mg patients achieved significant improvements in AS symptoms, seen as early as Week 1 and sustained through one year of treatment , Secukinumab is the first selective IL-17A inhibitor to significantly improve signs and symptoms of ankylosing spondylitis (AS) versus placebo in Phase III studies , Up to 40% of AS patients have inadequate or no response to standard of care anti-TNF (tumor-necrosis-factor) medicines

Pharmacology - Health - 12.11.2014
Novartis and Malaria No More help fulfill malaria treatment goal in Zambia by raising funds for three million treatments through Power of One
Power of One campaign, supported by exclusive treatment sponsor Novartis, raises funds for three million treatments for children with malaria Novartis associates rallied behind Power of One to fund c

Pharmacology - Health - 10.11.2014
Novartis to reveal landmark Phase III data for AIN457 (secukinumab) in psoriatic arthritis and ankylosing spondylitis at ACR 2014
Detailed results of four pivotal Phase III studies of secukinumab in psoriatic arthritis (PsA) and ankylosing spondylitis (AS) to be presented for the first time at ACR 2014 Secukinumab is the first selective interleukin-17A (IL-17A) inhibitor with Phase III data to demonstrate efficacy and improve symptoms in patients with PsA and AS Data will include study results from FUTURE 1 and FUTURE 2 in PsA and MEASURE 1 and MEASURE 2 in AS; data to be

Pharmacology - Health - 06.11.2014
Novartis announces outcome of FDA advisory committee meeting for multiple myeloma investigational compound LBH589
Committee votes against recommending LBH589 plus bortezomib and dexamethasone for patients with previously treated multiple myeloma LBH589 has the potential to be an important treatment option for mu

Business / Economics - Pharmacology - 28.10.2014
Novartis delivered solid sales growth with strong margin expansion and major innovation in the third quarter
Net sales up 4% (+5% cc) in Q3, with operating margin increase across Q3 and 9M Net sales of USD 14.7 billion grew 4% (+5% cc ) in Q3 Strong operating income growth in Q3 of 14% (+18% cc) Core

Business / Economics - Pharmacology - 26.10.2014
Novartis announces divestiture of influenza vaccines business to CSL for USD 275 million
CSL to acquire Novartis influenza vaccines business, including development pipeline, for USD 275 million Announcement follows a transaction announced on April 22, 2014 to divest the non-influenza seg

Pharmacology - 23.10.2014
Roche and Novartis will rise above the city of Basel
Roche presented development plans for its Basel site. Over the next 10 years, Roche will invest 3 billion Swiss francs in the development of its Basel site.

Health - Pharmacology - 23.10.2014
Novartis AIN457 (secukinumab) meets primary endpoint in two Phase III studies in ankylosing spondylitis, a debilitating joint condition of the spine
Secukinumab is the first selective IL-17A inhibitor to meet primary endpoint in two pivotal Phase III studies showing improvement in active ankylosing spondylitis (AS) patients' symptoms versus placebo AS is a painful, progressively debilitating condition associated with inflammation of the spine, causing irreversible consequences that significantly reduce patients' mobility and quality of life , Up to 40% of patients have an inadequate or no re

Health - Pharmacology - 23.10.2014
Stopping anti-CCL2 breast cancer treatment aggravates the disease
Mohamed Bentires-Alj and his team at the Friedrich Miescher Institute for Biomedical Research (FMI) together with scientists from the Novartis Institutes for BioMedical Research (NIBR) show in a study that a promising therapeutic approach for metastatic breast cancer elicits deleterious effects after cessation of the treatment.

Pharmacology - Health - 20.10.2014
Novartis announces FDA Advisory Committee unanimously recommends approval of AIN457 (secukinumab) for patients with moderate-to-severe plaque psoriasis
Biologics License Application (BLA) for secukinumab, a "first-in-class" IL-17A inhibitor, is currently under FDA review with an anticipated action date in early 2015 FDA Advisory Committee recommendation based on efficacy and safety outcomes of 10 Phase II/III clinical studies of secukinumab in moderate-to-severe plaque psoriasis Affecting 7.5 million Americans, psoriasis may negatively impact daily life and is associated with increased r

Health - Pharmacology - 15.10.2014
Novartis announces CTL019 data published in NEJM demonstrating efficacy in certain patients with acute lymphoblastic leukemia (ALL)
Preliminary study results show 27 of 30 pediatric and adult patients with relapsed/refractory (r/r) ALL (90%) experienced complete remissions with personalized cell therapy, CTL019 Largest published cohort to date for CTL019, which served as the basis for recent Breakthrough Therapy designation from the FDA Sustained remissions of up to two years in r/r ALL patients with six-month event-free survival of 67% and overall survival of 78% Novartis a

Pharmacology - Health - 10.10.2014
Novartis data at EADV show consistent efficacy of AIN457 (secukinumab) in clearing skin of psoriasis patients
New analyses of Phase III data show consistent efficacy in clearing psoriasis skin with AIN457 (secukinumab) regardless of how bad patients' disease is at start of treatment Significant positive responses to secukinumab seen in patients with severe psoriasis at start of treatment Significant positive relationship between achieving clear to almost clear skin and psoriasis patients' health-related quality of life, as shown by additional secukinuma

Pharmacology - 09.10.2014
Roche’s Perjeta regimen significantly extends the lives of people with metastatic breast cancer
Genentech, the US subsidiary of Roche, announced final survival results from the Phase III «Cleopatra» study, which showed that adding Perjeta to Herceptin and docetaxel chemotherapy extended the lives of people with previously untreated HER2-positive metastatic breast cancer by 15.7 months. According to Dr. Sandra Swain, an oncologist and professor at Georgetown University, this survival improvement is "unprecedented among studies of metastatic breast cancer”.

Pharmacology - 09.10.2014
Novartis and Bristol-Myers Squibb collaborate for developing a cancer-combo treatment
Most experts believe that combining immunotherapies with existing treatment options such as chemotherapies, radiation, targeted cancer therapies (and importantly also with cancer vaccines, many of wh

Pharmacology - Health - 07.10.2014
Roche and Novartis Venture Funds’ portfolio company Alios acquired for a record price tag
Johnson & Johnson announced a definitive agreement to acquire Alios BioPharma, a privately held clinical stage biopharmaceutical company focused on developing therapies for viral diseases, for approximately $1.75 billion, all cash with no strings attached.

Pharmacology - Health - 06.10.2014
Novartis announces clinical collaboration to evaluate Bristol-Myers Squibb’s novel immunotherapy in combination treatments for NSCLC
Phase I/II studies will evaluate Zykadia(TM), INC280 and EGF816 in combination with Bristol-Myers Squibb's investigational immunotherapy Opdivo Combination studies will evaluate compounds that have d

Health - Pharmacology - 01.10.2014
Novartis showcases dermatology leadership on International Urticaria Day announcing new data to be presented at EADV 2014
New data for the IL-17A inhibitor AIN457 (secukinumab) in psoriasis and Xolair in Chronic Spontaneous Urticaria (CSU) at EADV to highlight benefit to patients' quality of life Data continue to reinforce the landmark Phase III results of secukinumab in psoriasis and Xolair in CSU that showed consistent, fast efficacy and acceptable safety - Important head-to-head trial of secukinumab versus Stelara (CLEAR), powered to evaluate superiority in clea

Health - Pharmacology - 27.09.2014
Patients lived average of 18 months without cancer progressing when taking Novartis’ Zykadia(TM) as their first ALK inhibitor for ALK+ NSCLC
Longest median progression-free survival (PFS) ever reported in this ALK+ non-small cell lung cancer patient population, most who received prior chemotherapy Zykadia (ceritinib) achieved overall resp

Health - Pharmacology - 27.09.2014
Novartis drug Afinitor is first treatment for advanced pancreatic NET to provide overall survival of more than 3.5 years in Phase III trial
Afinitor led to an unprecedented median overall survival of 44 months, which represents a clinically meaningful while not statistically significant improvement Pancreatic NET (pNET) affects about 2&p

Health - Pharmacology - 26.09.2014
Novartis drug Signifor LAR recommended by CHMP for EU approval to treat patients with rare hormonal disorder acromegaly
Acromegaly is an endocrine disorder caused by elevated growth hormone (GH) and insulin-like growth factor-1 (IGF-1) levels Signifor LAR (pasireotide) represents a potential new option for acromegaly

Health - Pharmacology - 26.09.2014
Roche launches Global Access Program for HIV viral load testing
Roche launches Global Access Program for HIV viral load testing Program expands access to care supporting the Diagnostics Access Iniative Roche announced today the launch of a new Global Access Progr

Health - Pharmacology - 25.09.2014
Novartis AIN457 (secukinumab) is the first ever IL-17A inhibitor to meet primary endpoint in two Phase III studies in psoriatic arthritis
Secukinumab met primary and key secondary endpoints in two pivotal Phase III studies showing superiority to placebo in patients with adult onset psoriatic arthritis (PsA) PsA is a debilitating, long-lasting condition that causes inflammation of joints and skin and affects up to 30% of people with psoriasis globally , Many people with PsA do not respond to current standard of care, with approximately 45% of people dissatisfied with current treatm

Pharmacology - Health - 19.09.2014
Novartis data in The Lancet Oncology show LBH589 offers 4-month increase in median PFS for patients with multiple myeloma
Results show statistically significant and clinically relevant increase in median progression-free survival with LBH589 plus bortezomib and dexamethasone LBH589, a first-in-class treatment for patients with relapsed/refractory multiple myeloma if approved, helps extend benefit of standard-of-care therapy First Phase III study to demonstrate superiority of a three-drug over two-drug combination in this patient population Multiple myeloma, the sec

Pharmacology - Health - 17.09.2014
Novartis presents oncology research advances with new data on Zykadia(TM), Afinitor and key pipeline compounds at ESMO 2014
Latest Zykadia data in patients with ALK+ non-small cell lung cancer, including updated brain metastases analysis from pivotal trial Final overall survival data from Phase III trial of Afinitor in ad

Health - Pharmacology - 15.09.2014
Novartis invests in CAR-T development centre on Penn Medicine Campus
The University of Pennsylvania informed in a press release about an important milestone in its alliance with Novartis.

Health - Pharmacology - 13.09.2014
Novartis demonstrates leadership in ophthalmology with new products and over 40 abstracts at EURETINA
Retrospective analysis of US claims data suggests risk of endophthalmitis is 65% higher in patients treated with aflibercept than those treated with Lucentis Presentations discuss safety of Jetrea in

Pharmacology - Health - 12.09.2014
New data confirm high efficacy of Gilenya
A key treatment goal for patients with MS is 'no evidence of disease activity' (NEDA), currently defined as no relapses, MRI lesions and disability progression Including MS-related brain shrinkage (brain volume loss) as a fourth key measure captures underlying damage that begins early in MS and is associated with loss of function The likelihood of achieving NEDA across four key measures was more than four-times greater in patients treated with G

Pharmacology - Life Sciences - 10.09.2014
Gilenya data confirm reducing brain shrinkage matters
Brain shrinkage is associated with a loss of physical and cognitive function and occurs at a faster rate in people with MS than those without the disease New data showed patients who had the highest rates of brain shrinkage (brain volume loss) at two years had a higher risk of disability progression at four years Separate analyses showed that patients continuously treated with Gilenya for six years had sustained low rates of brain shrinkage The

Health - Pharmacology - 07.09.2014
Novartis data at ERS 2014 show once-daily Ultibro Breezhaler is superior in reducing COPD flare ups compared to Seretide *
Once-daily Ultibro Breezhaler reduced exacerbations (flare ups) by 31% compared to twice-daily Seretide Accuhaler * in moderate-to-severe COPD patients LANTERN study further confirmed superiority of Ultibro Breezhaler in improving lung function compared to Seretide in moderate-to-severe COPD patients First presentation of LANTERN trial at European Respiratory Society International Congress involving over 700 COPD patients Basel, September 7, 201

Pharmacology - Life Sciences - 03.09.2014
Gilenya data at ACTRIMS-ECTRIMS to show Novartis is redefining MS treatment goals for patients
'No evidence of disease activity' (NEDA), the ultimate treatment goal in MS, is currently assessed by measuring relapses, MRI lesions and disability progression New Gilenya data will highlight importance of brain shrinkage as NEDA fourth key measure, giving physicians more complete assessment of MS disease in patients Separate analyses will confirm the clinical relevance of brain shrinkage based on its association with future long-term MS disabi

Pharmacology - Health - 02.09.2014
Novartis to unveil new data from three key clinical trials at European Respiratory Society International Congress 2014
First presentation of LANTERN study to confirm superior efficacy of once-daily Ultibro Breezhaler versus Seretide Accuhaler * in COPD patients QUANTIFY study to show superiority of Ultibro Breezhaler in lung function and shortness of breath versus tiotropium plus formoterol New data from GLISTEN study will provide important evidence for the benefits of once-daily Seebri Breezhaler as add on therapy to LABA/ICS** Basel, September 2, 2014 - Novart

Health - Pharmacology - 30.08.2014
Novartis’ LCZ696 cut cardiovascular deaths by 20%
Study showed significantly more HF-REF patients on LCZ696 regimen were alive, had fewer hospitalizations than those given enalapril regimen On all-cause mortality, LCZ696 doubled the effect that enalapril, an ACE-inhibitor, previously showed vs placebo when added to current best treatment for HF-REF , 26 million people across US and Europe live with heart failure , facing high risk of death and poor quality of life , Basel, August 30, 2014 - Tod

Health - Pharmacology - 25.08.2014
Novartis experts and future scientific leaders meet at International BioCamp 2014 to consider ’The Race Against Time’
Global experts present potential solutions to support healthy aging from Novartis businesses and R&D organization The 11th annual event brings 60 top university students from 25 countries and ter

Pharmacology - Health - 20.08.2014
Novartis provides drug candidate compounds to TB Alliance
Exclusive worldwide license from Novartis includes a novel class of drugs that is active against drug sensitive and multi-resistant strains of tuberculosis Basel, August 20, 2014 - Novartis has signed an exclusive worldwide licensing agreement with the Global Alliance for TB Drug Development (TB Alliance) for compounds to fight tuberculosis (TB) that have been discovered at the Novartis Institutes for Tropical Diseases (NITD).

Health - Pharmacology - 11.08.2014
Novartis to showcase heart failure leadership at ESC Congress 2014 with results on new first of its type medicine LCZ696
LCZ696 significantly reduced cardiovascular deaths in head to head study against enalapril, in addition to current best treatment, in patients with HF-REF PARADIGM-HF is the largest heart failure study ever conducted - stopped early in March 2014 due to compelling efficacy , LCZ696 recently granted FDA Fast Track status - rolling submission expected to be complete by end of year Basel, August 11, 2014 - New data revealing the reduction in cardio

Pharmacology - Health - 07.08.2014
EU approves Roche’s Avastin for most difficult to treat form of ovarian cancer
Roche announced that the European Commission (EU) approved the use of Avastin in combination with chemotherapy as a treatment for women with recurrent ovarian cancer that is resistant to platinum-containing chemotherapy.

Pharmacology - Health - 07.08.2014
Ebola-vaccine of Okairos gets «Fast Track Status» of FDA
Viral diseases like Ebola aren't regarded as commercially interesting; therefore research usually gets stuck in the preclinical phase. But there may be a vaccine available in about one year from now. The Basel-based biotech company Okairos (GSK acquired the company in 2013) has an Ebola vaccine in the preclinical phase.

Health - Pharmacology - 06.08.2014
EU approves Roche’s Avastin for platinum-resistant recurrent ovarian cancer
Basel, 06 August 2014 EU approves Roche's Avastin for platinum-resistant recurrent ovarian cancer First new treatment option for women in Europe in more than 15 years for most difficult to treat form of ovarian cancer Roche announced today that the European Commission (EU) approved the use of Avastin (bevacizumab) in combination with paclitaxel, topotecan, or pegylated liposomal doxorubicin chemotherapy as a treatment for women with recurrent ovarian cancer that is resistant to platinum-containing chemotherapy.

Pharmacology - 31.07.2014
Incyte collaborates with Genentech to evaluate combination of two novel cancer immunotherapies
Incyte Corporation announced a clinical trial agreement with Genentech, a subsidiary of Roche, to evaluate the safety, tolerability and preliminary efficacy of Incyte's oral indoleamine dioxygenase-1

Pharmacology - 31.07.2014
Roche and Canadian venture capital fund AmorChem jointly focus on myotonic muscular dystrophy 1
Roche and AmorChem announced a collaboration to discover novel small molecule disease-modifying therapy for the treatment of myotonic muscular dystrophy 1 (known as Steinert's disease).

Health - Pharmacology - 30.07.2014
KAE609 shows promise as next generation treatment for malaria
KAE609 is the first antimalarial drug candidate with a novel mechanism of action to achieve positive clinical proof-of-concept in over 20 years KAE609 was tested in adult patients with uncomplicated malaria and showed a median parasite clearance time of 12 hours, including in patients with resistant infections For more than a decade, Novartis has been a leader in the fight against malaria, setting the current gold standard for treatment and buil

Health - Pharmacology - 30.07.2014
AstraZeneca and Roche announce a collaboration to develop a diagnostic test for the treatment of lung cancer
AstraZeneca has announced a partnership with Roche to develop a plasma-based companion diagnostic test to support the development of AZD9291, a clinical stage compound to treat patients with non-small-cell lung cancer (NSCLC) who are resistant to initial treatment.

Health - Pharmacology - 29.07.2014
Novartis vaccine Bexsero sees high uptake in first large-scale public vaccination program to help protect against devastating meningitis B
Program in Québec's Saguenay-Lac-Saint-Jean region is the first public campaign globally to offer Bexsero to all from 2 months to 20 years of age More than 45,000 infants, young children and adolesce

This site uses cookies and analysis tools to improve the usability of the site. More information. |